Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma (DMV)

This study has been completed.
Information provided by (Responsible Party):
University of California, San Francisco Identifier:
First received: September 25, 2009
Last updated: June 30, 2015
Last verified: June 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2010
  Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)